Vnitr Lek 2012, 58(1):52-55

Hyponatraemia associated with the syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) - options for treatment

M. Rudnay1, P. Hrabčáková2, I. Lazúrová1,*
1 I. interná klinika Lekárskej fakulty UPJŠ a UN L. Pasteura Košice, Slovenská republika, prednostka prof. MUDr. Ivica Lazúrová, CSc.
2 Klinika geriatrie a ošetrovateľstva Lekárskej fakulty UPJŠ Košice a Vysokošpecializovaného odborného ústavu geriatrického sv. Lukáša Košice, Slovenská republika, prednosta doc. MUDr. Marián Sninčák, PhD., mim. prof.

Hyponatremia is the most common electrolyte imbalance in outpatients and hospital inpatients and the syndrom of inappropriate secretion of antidiuretic hormone (SIADH) is one of the common causes of euvolemic hyponatremia. Recent studies showed significantly higher mortality and morbidity of hyponatriemic patients compared to normonatriemic controls. Moreover the morbidity and mortality of hyponatremic patients significantly increases in nontreated in comparison to those with the therapy. Clinical consequences of hyponatremia in SIADH could be devided according to stage of the disorder. The cerebral oedema with its symptoms (letargy, weakness, nausea, coma) is the most dangerous clinical feature. Clinical symptoms of hyponatremia also depend on how rapid the change of natremia is. Therefore the early diagnosis of disturbance and treatement are necessary. Not only acute but also chronic hyponatriemia must be treated. In the correction the restriction of water intake, loop diuretics (together with hypertonic solution of NaCl), demeclocyclin, urea and litium can be used. The blockers of vasopresin receptors - vaptans are perspective in treatment of patients with hyponatremia.

Keywords: hyponatremia; syndrom of inappropriate secretion of antidiuretic hormone; vaptans

Received: July 12, 2011; Published: January 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rudnay M, Hrabčáková P, Lazúrová I. Hyponatraemia associated with the syndrome of inappropriate antidiuretic hormone hypersecretion (SIADH) - options for treatment. Vnitr Lek. 2012;58(1):52-55.
Download citation

References

  1. Dzúrik R, Fedelešová V. Poruchy bilancie vody a elektrolytov. In: Ďuriš I et al (eds). Princípy internej medicíny 2. časť. Bratislava: SAP 2001: 1344-1348.
  2. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol 2010; 162 (Suppl 1): S5-S12. Go to original source... Go to PubMed...
  3. Sajadieh A, Binici Z, Mouridsen MR et al. Mild hyponatremia carriers a poor prognosis in community subjects. Am J Med 2009; 122: 679-686. Go to original source... Go to PubMed...
  4. Gill G, Huda B, Boyd A et al. Characteristics and mortality of severe hyponatraemia - a hospital based study. Clin Endocrinol 2006; 65; 246-249. Go to original source... Go to PubMed...
  5. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM 2006; 99: 505-511. Go to original source... Go to PubMed...
  6. Trejbalová Ľ, Podoba J. Syndróm inadekvátnej sekrécie antidiuretického hormónu. Interná Med 2005; 5: 9-12.
  7. Fenske W, Störk S, Blechschmidt A et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94: 123-129. Go to original source... Go to PubMed...
  8. Fenske W, Allolio B. The syndrome of inappropriate secretion of antidiuretic hormone: diagnostic and therapeutic advances. Horm Metab Res 2010; 42: 691-702. Go to original source... Go to PubMed...
  9. Zietse R, van der Lubbe N, Hoorn EJ. Current and future treatment options in SIADH. NDT Plus 2009; 2 (Suppl 3): iii12-iii19. Go to original source... Go to PubMed...
  10. Hoorn EJ, van der Lubbe N, Zietse R. SIADH and hyponatraemia: why does it matter? NDT Plus 2009; 2 (Suppl 3): iii5-iii11. Go to original source... Go to PubMed...
  11. Verbalis JG, Barsony J, Sugimura Y et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010; 25: 554-563. Go to original source... Go to PubMed...
  12. Sherlock M, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: current and future management options. Eur J Endocrinol 2010; 162 (Suppl 1): S13-S18. Go to original source... Go to PubMed...
  13. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112. Go to original source... Go to PubMed...
  14. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009; 11: 14-19. Go to original source... Go to PubMed...
  15. Li-Ng M, Verbalis JG. Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evidence 2009; 4: 83-92. Go to original source...
  16. Sterns RH, Cappuccio JD, Silver SM et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4: 1522-1530. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.